Skip to main content

Uveal melanoma · 2026

Uveal melanoma: from local control to a systemic pathway

Treating the primary ocular tumour is one stage of care. The next steps are risk assessment, surveillance and a structured pathway if metastatic disease is detected.

Uveal melanoma arises in the uveal tract of the eye. Its biology and oncology pathway differ from cutaneous melanoma, so diagnosis, surveillance and treatment decisions require a dedicated framework.

For patients and clinicians

A visual map from local control and risk assessment to metastatic decision nodes and multidisciplinary treatment. — A visual map from local control and risk assessment to metastatic decision nodes and multidisciplinary treatment.Tap the image to open the full-size vector infographic.

Start hereSymptoms and diagnosisWhat you may notice, why there may be no symptoms, and how a suspicious lesion is assessed →

Core principle: local control of the primary tumour does not end the oncology pathway.

A pathway, not one procedure

What follows treatment of the primary ocular tumour.

2Risk and surveillance

Tumour biology, the liver and risk-adapted follow-up.

3Metastatic disease

Phenotype, HLA, burden, tempo and patient condition.

Systemic, liver-directed, trials, MDT and referral.

Choose your level of detail

For patients

Understand the next step

Symptoms and how uveal melanoma is detected How UM differs from skin melanoma What happens after local treatment Why the liver matters

For clinicians

Evidence + decision framework

Risk-adapted surveillance HLA-A*02:01 and tebentafusp Liver-directed treatment

Key references

← Back to uveal melanoma hub